Yingtao Lin

Fuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial.

Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial.

Journal: Gynecologic oncology

Published: January 19, 2026

Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China.

Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China.

Journal: Frontiers in pharmacology

Published: November 09, 2025

Evaluation of large language models for nursing support in maternal venous thromboembolism care.

Evaluation of large language models for nursing support in maternal venous thromboembolism care.

Journal: Frontiers in public health

Published: November 05, 2025

Cost‑effectiveness analysis of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer in China.

Cost‑effectiveness analysis of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer in China.

Journal: Surgical endoscopy

Published: August 22, 2025

Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.

Molecular and Immune Correlates of Response to First-Line De-escalated Chemotherapy plus Penpulimab and Anlotinib in Advanced Cervical Cancer.

Journal: Cancer discovery

Published: July 28, 2025

Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.

Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.

Journal: Journal of gynecologic oncology

Published: July 28, 2025

Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China.

Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China.

Journal: Risk management and healthcare policy

Published: July 14, 2025

Minimally invasive versus open surgery in uterine serous carcinoma: impact on recurrence and survival in a multicenter cohort.

Minimally invasive versus open surgery in uterine serous carcinoma: impact on recurrence and survival in a multicenter cohort.

Journal: Frontiers in oncology

Published: July 14, 2025

Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial.

Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial.

Journal: BMJ open

Published: May 19, 2025

Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China.

Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China.

Journal: Therapeutic advances in medical oncology

Published: May 15, 2025

Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study.

Real-world data of cadonilimab in recurrent or metastatic cervical cancer in China: a multicentric study.

Journal: Frontiers in immunology

Published: April 14, 2025

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis.

Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis.

Journal: Annals of medicine

Published: March 25, 2025

Showing 1-12 of 21

Last Updated: 09/26/2026